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SUMMARY - Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the
central nervous system, characterized by multifocal inflammatory destruction of myelin, axonal
damage and loss of oligodendrocytes. The disease is carried through two stages: inflammatory and
degenerative. The most common form of disease in approximately 85%of the cases is RRMS (relap-
sing-remitting form). The treatment ofMS is devided into: treatment of the acute phase of illness,
prevention of new relapses and disease progression, and symptomatic treatment. Most of the chan-
ges in treatment of multiple sclerosis and most of the news in recent years concerning new drugs
are used in the treatment of progression of the disease and prevention of disease relapses. Some of
these drugs are registrated in most Europian countries and USA, and others are in various stages
of research.
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Introduction
Multiple sclerosis (MS) is an autoimmune inflam-
matory demyelinating disease of the central nervous
system characterized by multifocal inflammatory de-
struction of myelin, axonal damage and loss of oli-
godendrocytes. In the pathogenesis of the disease,
activated T-lymphocytes are involved, causing en-
dothelial changes in the blood-brain barrier, secreting
inflammatory mediators and stimulating the cascade
of inflammation. In the disease development, inter-
feron gamma plays a significant role; it is produced
in activated T-cel1 lymphocytes (THI class) and ac-
tivates macrophages to protease and tumor necrosis
factor (TNF) production, which in turn destroy oli-
godendrocytes, leading to the onset and progression
of the disease.
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The most common form of disease, found in ap-
proximately 85% of cases is the relapsing-remitting
form (RRMF). The treatment of MS is divided into
treatment of the acute phase of the disease, prevention
of new relapses and disease progression, and symp-
tomatic treatment'.
Treatment ofMultiple Sclerosis
In newly diagnosed patients and in the stage of
acute exacerbation or disease relapses, we apply cor-
ticosteroids as 'pulse corticosteroid therapy' using
methylprednisolone (Solumedrolv'") intravenously
500-1000 mg/day in 250 mL saline solution in short
infusions (30-45 minutes) for 5 days. Along with cor-
ticosteroids, histamine blockers (H2 receptors, ran-
itidine), acetazolamide and potassium replacement
therapy are administered for three weeks. The corti-
costeroid side effects are hirsutism, osteoporosis, acne,
cataract, hypertension, duodenal ulcer, psychosis, and
blood glucose impairment. Contraindications for the
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use of corticosteroids are active inflammatory disease,
poorly regulated diabetes and psychosis.
The patients in the acute stage of the disease that
do not respond to corticosteroid therapy can be treat-
ed with plasmapheresis, i.e. seven successive plasma-
pheresis procedures every other day or intravenous im-
munoglobulins (IVIg) at a dose of 0.4 g/kg daily for
5 days. Side effects of immunoglobulin therapy may
be related to their intravenous administration, dosage
or transmission of infectious agents (e.g., hepatitis C
virus) and prions. The most important side effects as-
sociated with the intravenous administration of im-
munoglobulins include headache, fever, shivering, Ia-
cial flushing, back pain, and anaphylactic shock as the
most severe one. Side effects associated with dosage
of intravenously administered immunoglobulins are
hematologic (neutropenia and lymphopenia, and in-
creased plasma viscosity), dermatologic (rash, eczema
and urticaria), aseptic meningitis and renal (tubular)
damage2,3.
Immunomodulators and immunosuppressants are
used in the prevention of the disease relapse. Since
1993, the immunomodulatory therapy with inter-
ferons that change the natural course of the disease
in MS patients has been used in the prophylactic
treatment of disease exacerbation. The mechanism
of action of interferons is not fully understood, but
they are known to have antiviral, immunomodula-
tory and antiproliferative effects. They increase the
number and activation of CD 8 suppressor cells,
their count being reduced in MS patients, inhibit-
ing the secretion of interferon gamma, which favors
the development and progression of the disease, and
inhibits the interferon gamma-induced expression of
MHC class II antigen at glial cells. They also lead to
lymphotoxin (LT) and TNF decrease, which impairs
oligodendrocyte function and promotes astrogliosis
that reduces the possibility for activated immune
cells to cross the blood-brain barrier and increases
TH2 cytokines, interleukin 4 (IL-4) and IL-10 by
favoring their production as well as the production
of transforming growth factor beta (TGF beta) in T
helper cells.
In the world, recombinant beta interferons are
used in the treatment of MS. The glycolyzed form
is interferon la, which is similar to natural human
interferon beta (Rebif", Merck-Serono and Avon-
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ex®, Biogen Idee), was registered in Europe, Canada
and the USA in 1998. The non-glycolyzed form is
interferon beta 1b (Betaserorr", Berlex Laborato-
ries, Betaferon, Bayer-Schering AG, and Extavia,
Novartis)!". There was a number of important clini-
cal trials that tested and compared the efficacy of
these interferons in the treatment of patients suffer-
ing from various forms of MS, primarily in patients
with RRMS, according to the frequency of drug us-
age (once a week, three times a week, or every other
day), the length of drug usage (one year, two years,
or several years), the way of administration (subcu-
taneously, s.c., or intramuscularly, i.m.), drug dos-
age, and disability at the beginning and at the end
of drug administration on the EDSS scale (scale of
disability ofMS patients in which disability is scored
from 0 for normal neurologic status to 10 for death).
The efficacy of each beta interferon was assessed by
the number of relapses, disease progression, reduc-
tion of disability on EDSS scale by 1 point, reduc-
tion in the number of active demyelinating lesions
on magnetic resonance (MR), and reduction in the
extent of lesions on MRI during drug administra-
tion. The best known clinical studies were as follows:
the first multicenter, randomized, double blind, pla-
cebo controlled study from 1993 in RRMS patients
(comparison of interferon beta 1b and placebo);
PRISMS study (comparison of two different doses
of beta interferon 1 a ~ Rebif> 22 mcg (6 MIU) s.c.
three times a week and Rebif> 44 mcg (12 MIU)
s.c. three times a week)'; SPECTRIMS (Secondary
Progressive Efficacy Clinical Trial in MS); ETOMS
(Early Treatment ofMultiple Sclerosis with Rebif"),
EVIDENCE (Evidence for Interferon Dose Effect:
European-North American Comparative Efficacy
trials, comparative study of Efficacy of Rebif> and
Avonex"); and OWIMS (comparison of Rebif> in
a dose of 22 mcg s.c. and 44 mcg s.c. once a week).
The latest studies, some ofwhich are still in progress,
are INCOMIN (Independent Comparison oflnter-
ferons, following up patients treated with interferon
beta 1 b 250 mcg every other day s.c. and interferon
beta 1 a 30 mcg i.m. once a week, showing the more
frequent usage to be more efficient); BEYOND (a
study with a twofold dose of interferon beta 1 b, Be-
taferone", which is still in the second phase); and
BENEFIT (Betaferone? in Newly Emerging mul-
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tiple sclerosis For Initial Treatment), with initial ad-
ministration of interferon beta 1 b, Beraferone", in
newly detected patients in comparison with placebo.
The latest study the three-year results of which have
been published this year showed the use of interferon
beta 1 b, Beraferone", in the early stages of the dis-
ease, in comparison with placebo, to delay the time
to clinically definitive form of disease (CDMS), to
significantly reduce the number of relapses and dis-
ability, and to increase the quality of life in patients.
Meta-analysis of randomized placebo controlled
studies of interferons in patients with RRMS (pub-
lished during the 1993-2002 period) using the Co-
chrane Collaboration method has shown them to
mildly reduce the number of patients with disease
exacerbation in the first year of treatment, with un-
certain clinical efficacy after the first year of inter-
feron administration; additional studies on the long
term use of recombinant forms of beta interferon and
cost-effect analysis are necessary>".
The quality of MS treatment with interferon beta
was assessed in the Q.UASIMS study that included
510 centers in 11 countries and compared treatment
with different interferon beta preparations. This study
showed similar efficacy of all beta interferons avail-
able, being administered either as initial or follow up
therapy for RRMS7-18
In Croatia, there are strict criteria concerning in-
dications and contraindications for the treatment with
interferon beta. Treatment with interferon beta may
be related to the occurrence of neutralizing antibod-
ies. Immunologic studies have shown that neutral-
izing antibodies can extend biological lifetime of cy-
tokines and have beneficial effect. The occurrence of
neutralizing antibodies with the use of interferon may
be related to the loss ofefficiency. Side effects of inter-
feron beta are 'flue-like' symptoms, skin lesions at the
site of application, elevated liver enzymes, depression,
and allergies. Anemia may be present with the use of
Avonex'> and cytopenia with Betaseronw.
Among other medications used in therapy of MS,
mention should be made of the immunomodulator
Copaxonc" (glatiramer acetate) in a dosage of 20
mg s.c. once a day", which is on the Croatian Insti-
tute for Health Insurance list since September 2006,
along with immunosuppressants (Novartone, mitox-
antron hydrocloride in a dosage of 8-12 mg/m- i.v.,
Azatioprine'P Imuran", cyclophosphamide Cytoxan",
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cyclosporine A and methotrexate). Currently, highest
expectations are put on therapy with mitoxantrone
hydrochloride, a synthetic anaplastic agent with anti-
inflammatory effect. This medication is prescribed
for SPMS, and has been confirmed to reduce clinical
symptoms and lesion activity on MRI. The dosage of
medication is cumulative, and because of its cardio-
toxicity it has a strictly limited total life dose of up to
120-140 mg i.v.'.
Additionally, full irradiation of lymphatic nodes
can be performed over a 5-6 weeks.
Recently, new studies on the use of stem cell
transplantation in the treatment of severe forms of
MS (SPMS and PPMS) are emerging. This form of
treatment has been previously administered for other
autoimmune diseases such as systemic sclerosis and
rheumatoid arthritis'V''.
Monoclonal antibodies (Mabs) that also belong to
the class of biotechnological medications show prom-
ising results in the treatment of autoimmune and in-
flammatory diseases such as MS. Since they enable
selective modulation of defined molecules, they are an
attractive therapeutic option.
For different types ofMS, a large number ofmono-
clonal antibodies are currently studied: anti Til, anti
T12, anti T 4, anti CD3, anti CD4, anti CD 25, anti
CD20, and widely known anti CD52 (alemtuzumab),
clinical studies of which are in progress21,22 . One of
the monoclonal antibodies, anti alpha 4 integrin (na-
talizumab, Tysabri"), is already registered in America
and Europe for the treatment of rapidly progressive
forms of MS. Studies which confirm its efficacy are
AFFIRM (compares efficiency of Tysabri'" 300 mg
i.v. every four weeks vs. placebo every four weeks) and
SENTINEL (Tysabri'" in recommended dose is added
to therapy with Avonex'> in half of all patients, while
in the other half placebo is combined with Avonex'>
for 120 weeks). Patients that received Tysabri'" had a
significantly lower number and frequency of disease
relapses, reduced disability and lower number of ac-
tive lesions on MR23-25.
Today, orally administered drugs for use in MS are
also investigated, the best known of which is cladrib-
ine (2-chloro-2-deoxyadenosine, CdA), a synthetic
purine analog''- As for symptomatic treatment, the
management of spasticity, slackness, dysfunction of
miction, equilibrium, vertigo, tremor, pain and mood




Due to the large number of clinical studies of new
drugs for MS, it appears optimistic to expect a dis-
covery of increasingly effective medications for MS
therapy. Research is directed towards enhancement of
currently available medications (new formulations of
drugs already in use, e.g., beta interferon la, which is
less immunogenic, pegylated interferon beta prepara-
tions that have better pharmacokinetic properties and
can be administered less often), improved possibili-
ties of administration (by improving auto injectors),
research of oral drugs, usage of combination of drugs,
and better collaboration between patients and phy-
sicians, which is also very important for successful
treatment.
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Treatment of multiple sclerosis
Multipla skleroza (MS) je upalna autoimuna demijelinizacijska bolest sredrsnjega iiveanog sustava obiljeiena multifo-
kalnom upalnom destrukcijom mijelina, ostecenjem aksona i gubitkom oligodendrocita. Bolest se odvija kroz dvije faze,
upalnu i degenerativnu. NajcdCi oblik bolesti, u otprilike 85% slucajeva je RRMS (relapsno-remitentni oblik).
Lijecenje MS dijeli se na lqecenje akutne faze bolesti, prevenciju novih recidiva i progresije bolesti te simptomatsko
hjecenje. Posljednjih godina najvrse promjena i novih lijekova u lqecenju multiple skleroze rabi se u lqecenju odnosno spr-
jecavanju progresije bolesti te prevenciji recidiva bolesti. Neki od tih lijekova su registrirani u vecini europskih zemalja i u
Americi, a drugi su u razlicitim fazama istraiivanja.
Kljucne rijeci: Multipla skleroza ~ terapiJa;Imunosupresivi ~ terapiJskaprimjena; Interferon, beta ~ terapiJskaprimjena
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